DRUG RESISTANCE

18/06/2025 10:45 20:00

Poster and Exhibition Hall

Time	Session

10:45 20:00	Adquired resistance mechanisms to KRAS G12C inhibitors in lung cancer P-308 EACR25-0003 Marc Cucurull Salamero Poster Presenter Spain	Novel Topoisomerase I (Topo1) inhibitors with a non-Camptothecin core scaffold to overcome resistance to current Topo1-targeted drugs and ADCs P-309 EACR25-0051 Qun Dang Poster Presenter China	Chemotherapeutic Response and Resistance in a 3D MDA-MB 231Triple-Negative Breast Cancer Spheroid Model P-310 EACR25-0163 Beynon Abrahams Poster Presenter South Africa	Overcoming Gemcitabine Resistance in MDA-MB-231 Cells: A Synergistic Approach Using ABT-737 and NVP-BEZ235 Dual Inhibition of PI3K/mTOR P-311 EACR25-0209 Gizem Selimoglu Poster Presenter Turkey	Bacterial modulation of 5-FU chemoresistance in head and neck cancer P-312 EACR25-0229 Lee Mai Poster Presenter Australia	Investigating AMBRA1’s role as a prognostic biomarker of resistance for melanoma therapies P-313 EACR25-0247 Christina Tsiavou Poster Presenter Sweden	Variable responses to Akt kinase inhibition stem from non-genetic heterogeneity P-315 EACR25-0303 Colin Ratcliffe Poster Presenter United Kingdom	Acquisition of resistance to targeted therapies in lung cancer: mechanistic basis and suppressive strategies P-316 EACR25-0351 Jos Poster Presenter Portugal	BET inhibitor Birabresib synergizes with PARP inhibitor Talazoparib in urothelial cancer cell lines and patient-derived organoids P-317 EACR25-0379 Jutta Schmitz Poster Presenter Germany	Activation of the Integrated Stress Response to overcome multidrug resistance in cancer therapy P-318 EACR25-0505 Jorge Mota-Pino Poster Presenter Spain	Targeting DUSP6 to combat therapy resistance and brain metastasis in HER2-positive breast cancer P-319 EACR25-0601 Shruti Nitin Bhardiya Poster Presenter Finland	Understanding and targeting mechanisms of resistance to the cytidine deaminase biodegrader and gemcitabine combination in cancer P-320 EACR25-0637 Margot Cristol Poster Presenter France	KRAS silencing impacts chromatin organization and transcriptional activity in colorectal cancer cells P-321 EACR25-0651 S Poster Presenter Portugal	Characterization of TRIB2 role in pancreatic cancer chemoresistance P-322 EACR25-0659 In Poster Presenter Portugal	Identifying Therapeutic Vulnerabilities in KRASG12D-Resistant Pancreatic Cancer Using High-Throughput Drug Screening P-323 EACR25-0711 Manzila Kuerbanjiang Poster Presenter Germany	Potential therapeutic implication of Epithelial Protein Lost in Neoplasm (EPLIN) in head and neck cancer and chemotherapy resistance P-324 EACR25-0713 CAI WANG Poster Presenter United Kingdom	Combination therapy with YAP/TEAD and RAS inhibitors overcomes phenotypic cell plasticity-driven resistance in NRAS-mutated melanoma P-325 EACR25-0739 Mira Kahil Poster Presenter France	The interplay between mechanisms of resistance and therapeutic targets: identifying novel treatments for drug-resistant BRAFV600E pediatric high-grade glioma P-326 EACR25-0755 Rebecca Lehmann Poster Presenter Australia	Targeting ErbB receptor family to intercept therapy adaptation in ALK-positive lung cancer P-327 EACR25-0781 JIAHAO TAO Poster Presenter Italy	The Role of NRG-1 in Resistance to Targeted Cancer Therapies in ERBB2-Amplified Breast Cancer P-328 EACR25-0797 Mahtab Karbasian Poster Presenter Finland	Unraveling the Hidden Player: miR-188-5p at the Crossroads of DDR and PARP Inhibitor Resistance in Ovarian Cancer P-329 EACR25-0897 Elif Merve Ayd Poster Presenter Turkey	Decoding drug resistance in cervical cancer cell lines: an AKT-independent mechanism P-330 EACR25-0923 Nauf Bou Antoun Poster Presenter United Kingdom	Rituximab resistance shapes sensitivity to effector-cell mediated cytotoxicity in B-cell lymphoma P-331 EACR25-0975 Aleksandra Maria Kusowska Poster Presenter Poland	Crosstalk between oncogenic signaling pathways as driver of therapy resistance against small molecule inhibitors in Glioblastoma P-332 EACR25-0987 Mike van Heumen Poster Presenter Netherlands	Targeting Drug Resistance in Hepatocellular Carcinoma: Uncovering Metabolic Vulnerabilities for Therapeutic Re-Sensitization P-333 EACR25-1015 Dzeneta Halilovic Poster Presenter Luxembourg	Investigating estrogen receptor fusion proteins as a mechanism of resistance to endocrine therapies in breast cancer P-334 EACR25-1057 Anastasia Alataki Poster Presenter United Kingdom	Increased Sensitivity to BCL-2 Inhibition in EGFR-TKI Resistant NSCLC Cell Lines P-335 EACR25-1105 Madeleine Jares Poster Presenter Germany	SPOCK1 is Linked to Mesenchymal-like Features and Drug Resistance in Melanoma Cells Treated with BRAF and MEK Inhibitors P-336 EACR25-1107 Carme Sol Poster Presenter Spain	Combinatorial assessment of DXd-based antibody drug conjugates with DNA damage response inhibitors in ovarian and endometrial cancers P-337 EACR25-1127 Yongda Li Poster Presenter Ireland	Unraveling Therapeutic Resistance in Patients with Early-Stage HER2-Negative Breast Cancer in the I-SPY2 Clinical Trial P-338 EACR25-1205 Tam Binh Bui Poster Presenter United States	Pt1a and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma effect through RNA m6A methylation modification P-339 EACR25-1273 Yinjia Huang Poster Presenter Hong Kong, China	SOAT1 Promotes Methotrexate Resistance in Choriocarcinoma P-340 EACR25-1275 Mengxia Zheng Poster Presenter China	Creating Repotrectinib Resistance in a Ba/F3 SLC34A2-ROS1 NSCLC cell line P-341 EACR25-1297 Patrick Korthuis Poster Presenter Netherlands	Targeting Fascin as a Therapeutic Approach to Overcome Oxaliplatin Resistance in Colorectal Cancer P-342 EACR25-1307 Diogo Rafael Da Cruz Ribeiro Poster Presenter Spain	SRSF9-mediated alternative splicing impairs anti-tumor immunity and drives resistance to PD-L1/VEGF-A blockade in hepatocellular carcinoma P-344 EACR25-1407 Jie Luo Poster Presenter Hong Kong, China	Revealing Distinct Oxaliplatin Resistance Mechanisms in HCT116 Cells Through Genomic and Transcriptomic Analysis Under Continuous and Intermittent Treatment Regimens P-345 EACR25-1413 Gamze Yilmaz Poster Presenter Turkey	An unbiased in vitro screen for uncovering HER2 drug resistance mutations P-346 EACR25-1461 Iman Farahani Poster Presenter Finland	Quantitative proteomics of drug-metabolizing enzymes and transporters in patients with appendix tumours P-347 EACR25-1467 Areti-Maria Vasilogianni Poster Presenter United Kingdom	Establishment of chemoresistant patient-derived tumor organoids (PDTO) to identify relevant biomarkers for second-line treatments in ovarian cancer P-348 EACR25-1477 Sahra Messaoudi Poster Presenter France	Lysosomal Ca2+ release via TRPML3 enhances drug sensitivity of gefitinib-resistance NSCLS cells P-349 EACR25-1569 Sei-Hoon Yang Poster Presenter Korea (Republic of)	SOS1 inhibition enhances the efficacy of and delays resistance to oncogene-targeted therapies in lung adenocarcinoma P-350 EACR25-1617 Robert L Kortum Poster Presenter United States	INTRINSIC MECHANISMS OF RESISTANCE TO CDK4/6 INHIBITORS IN LUMINAL METASTATIC BREAST CANCER P-351 EACR25-1655 Maribel Aybar Molina Poster Presenter Spain	Overcoming Antibody-Drug Conjugate Resistance in HER2-Positive Breast Cancer: Insights into Molecular Mechanisms and Targeted Therapeutic Approaches P-352 EACR25-1689 Queenie Yong Poster Presenter New Zealand	Chlorpromazine nanoparticles enhance anti-cancer effect of Doxorubicin nanoparticles preventing their extrusion P-353 EACR25-1707 Abhisek Mishra Poster Presenter India	Involvement of Androgen Receptor/miR-181a-5p/c-Met Axis in the Progression of Prostate Cancer P-354 EACR25-1709 Peyda Korhan Poster Presenter Turkey	miR-212-3p Down-Regulates the MAPK/ERK Pathway to Mitigate Oxaliplatin Resistance in Colorectal Cancer P-355 EACR25-1715 Tsai-Yi Hsu Poster Presenter Taiwan	Functional and molecular changes implicated in doxorubicin resistance in breast cancer P-356 EACR25-1777 Lenka Trnkova Poster Presenter Slovakia	Sensitization of ovarian cancers to ΡARΡ inhibitors by inductiοn of an ΗRD phenοtype: towards a medicine of precision based on UBE2Ν inhibitiοn. P-357 EACR25-1781 L Poster Presenter France	A not expected effect of longterm temozolomide treatment on resistance of glioblastoma cells – an in vitro study P-358 EACR25-1827 Claudia von Montfort Poster Presenter Germany	Intercellular Communication via Therapy-Induced Secretome Drives Chemoresistance in Ovarian Cancer Cells P-359 EACR25-1885 Polina Shnaider Poster Presenter Russia	On-target mutations confer resistance to WRN helicase inhibitors in Microsatellite Unstable Cancer Cells. P-360 EACR25-1893 GABRIELE PICCO Poster Presenter United Kingdom	The Role of AP-1 Target Transcript Vav3.1 in the Regulation of Osimertinib Resistance in Lung Adenocarcinoma P-361 EACR25-1999 Nazife Ege G Poster Presenter Turkey	Unravelling PARP inhibitor resistance mechanisms in ovarian cancer P-362 EACR25-2027 Adri Poster Presenter Spain	Identifying miR-7-5p/KEAP1/NRF2 and miR-122-5p/ADAM10/IL-6 signaling axes in Castration and Enzalutamide-resistant prostate cancer cells P-363 EACR25-2033 Ceyda Nur Zaim Poster Presenter Turkey	Targeting ferroptosis resistance by inhibiting SCD1 in TNBC enhances tumor response to immunotherapy. P-364 EACR25-2063 Quentin Herrera Garfia Poster Presenter Belgium	Tumor microenvironment determines immune resistance to chemoimmunotherapy in KRAS-mutant Non-Small Cell Lung Cancer: transcriptomic insights from a prospective cohort P-904 EACR25-2083 Raquel Herrero Poster Presenter Spain	Targeting BCL-2 proteins as a Strategy Against Therapy Persistency in TNBC P-365 EACR25-2121 T Poster Presenter Spain	Targeting Epigenetic Mechanisms to Overcome Drug Resistance in TaxaPlatin-Resistant Prostate Cancer P-366 EACR25-2193 Neslihan Y Poster Presenter Turkey	CDK12/13 inhibition can counteract Epithelial Ovarian Cancer chemoresistance P-367 EACR25-2239 Ilenia Pellarin Poster Presenter Italy	High resolution profiling of complex in vitro 3D lung cancer model to monitor resistance to immune checkpoint inhibitors P-368 EACR25-2279 Hortense PERDRIEAU Poster Presenter France	EGFR/SHP2-targeted antibody-drug conjugate for colorectal cancer theranostics P-369 EACR25-2319 Joana Filipa Santos Poster Presenter Portugal	Overcoming PARP inhibitor resistance in ovarian cancer: interest of the HDAC inhibitor belinostat P-370 EACR25-2375 Sterenn Guillemot Poster Presenter France	Reducing Glioblastoma Treatment Heterogeneity Through Tumor Treating Fields Application Coupled With tmCLIC1 Impairment by Metformin P-371 EACR25-2407 Michele Mazzanti Poster Presenter Italy	Cisplatin resistance hinders the response to CDK4/6 inhibitors in esophageal squamous cell carcinoma cells P-373 EACR25-2503 Marta Avalos Moreno Poster Presenter Belgium	Targeting AURKA Overcomes Gemcitabine Resistance in TP53-Mutated Cancers by Disrupting the Replication Stress Response P-374 EACR25-2593 Jian Wang Poster Presenter China